239 related articles for article (PubMed ID: 12140005)
1. Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting.
Eleopra R; Tugnoli V; Quatrale R; Gastaldo E; Rossetto O; De Grandis D; Montecucco C
Clin Neurophysiol; 2002 Aug; 113(8):1258-64. PubMed ID: 12140005
[TBL] [Abstract][Full Text] [Related]
2. Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C.
Morbiato L; Carli L; Johnson EA; Montecucco C; Molgó J; Rossetto O
Eur J Neurosci; 2007 May; 25(9):2697-704. PubMed ID: 17561839
[TBL] [Abstract][Full Text] [Related]
3. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans.
Eleopra R; Tugnoli V; Rossetto O; De Grandis D; Montecucco C
Neurosci Lett; 1998 Nov; 256(3):135-8. PubMed ID: 9855358
[TBL] [Abstract][Full Text] [Related]
4. Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.
Kutschenko A; Weisemann J; Kollewe K; Fiedler T; Alvermann S; Böselt S; Escher C; Garde N; Gingele S; Kaehler SB; Karatschai R; Krüger THC; Sikorra S; Tacik P; Wegner F; Wollmann J; Bigalke H; Wohlfarth K; Rummel A
Clin Neurophysiol; 2019 Jun; 130(6):1066-1073. PubMed ID: 30871800
[TBL] [Abstract][Full Text] [Related]
5. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human.
Eleopra R; Tugnoli V; Rossetto O; Montecucco C; De Grandis D
Neurosci Lett; 1997 Mar; 224(2):91-4. PubMed ID: 9086464
[TBL] [Abstract][Full Text] [Related]
6. [Use of botulinum neurotoxin therapy].
Mukai Y; Kaji R
Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
[TBL] [Abstract][Full Text] [Related]
7. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
Adler M; Keller JE; Sheridan RE; Deshpande SS
Toxicon; 2001; 39(2-3):233-43. PubMed ID: 10978741
[TBL] [Abstract][Full Text] [Related]
8. Different types of botulinum toxin in humans.
Eleopra R; Tugnoli V; Quatrale R; Rossetto O; Montecucco C
Mov Disord; 2004 Mar; 19 Suppl 8():S53-9. PubMed ID: 15027055
[TBL] [Abstract][Full Text] [Related]
9. Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A.
Rogozhin AA; Pang KK; Bukharaeva E; Young C; Slater CR
J Physiol; 2008 Jul; 586(13):3163-82. PubMed ID: 18467364
[TBL] [Abstract][Full Text] [Related]
10. Clinical duration of action of different botulinum toxin types in humans.
Eleopra R; Rinaldo S; Montecucco C; Rossetto O; Devigili G
Toxicon; 2020 May; 179():84-91. PubMed ID: 32184153
[TBL] [Abstract][Full Text] [Related]
11. [Use of botulinum neurotoxin for spasticity].
Mukai Y; Kaji R
Brain Nerve; 2008 Dec; 60(12):1421-6. PubMed ID: 19110753
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons.
Foran PG; Mohammed N; Lisk GO; Nagwaney S; Lawrence GW; Johnson E; Smith L; Aoki KR; Dolly JO
J Biol Chem; 2003 Jan; 278(2):1363-71. PubMed ID: 12381720
[TBL] [Abstract][Full Text] [Related]
13. Capsaicin protects mouse neuromuscular junctions from the neuroparalytic effects of botulinum neurotoxin a.
Thyagarajan B; Krivitskaya N; Potian JG; Hognason K; Garcia CC; McArdle JJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):361-71. PubMed ID: 19654265
[TBL] [Abstract][Full Text] [Related]
14. A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo.
Donald S; Elliott M; Gray B; Hornby F; Lewandowska A; Marlin S; Favre-Guilmard C; Périer C; Cornet S; Kalinichev M; Krupp J; Fonfria E
Pharmacol Res Perspect; 2018 Dec; 6(6):e00446. PubMed ID: 30519475
[TBL] [Abstract][Full Text] [Related]
15. Multiple domains of botulinum neurotoxin contribute to its inhibition of transmitter release in Aplysia neurons.
Poulain B; Wadsworth JD; Shone CC; Mochida S; Lande S; Melling J; Dolly JO; Tauc L
J Biol Chem; 1989 Dec; 264(36):21928-33. PubMed ID: 2574722
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F
Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565
[TBL] [Abstract][Full Text] [Related]
17. British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin.
Marion MH; Humberstone M; Grunewald R; Wimalaratna S
Pract Neurol; 2016 Aug; 16(4):288-95. PubMed ID: 26976927
[TBL] [Abstract][Full Text] [Related]
18. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor.
Rummel A; Häfner K; Mahrhold S; Darashchonak N; Holt M; Jahn R; Beermann S; Karnath T; Bigalke H; Binz T
J Neurochem; 2009 Sep; 110(6):1942-54. PubMed ID: 19650874
[TBL] [Abstract][Full Text] [Related]
19. The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia.
Delnooz CC; Veugen LC; Pasman JW; Lapatki BG; van Dijk JP; van de Warrenburg BP
Eur J Neurol; 2014 Dec; 21(12):1486-e98. PubMed ID: 25060697
[TBL] [Abstract][Full Text] [Related]
20. Botulinum neurotoxin for the treatment of movement disorders.
Kopanidis P; Das C
Aust J Gen Pract; 2018 Sep; 47(9):598-601. PubMed ID: 30244558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
